ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,562Medicare Part D Prescriptions Filled, Including Refills

Rank: 19 out of 113

$537K Total Retail Price of All Prescriptions

Rank: 25 out of 113

399 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
24% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Montana
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 399 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

19% of this provider’s 399 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

1% of this provider’s 9,359 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Montana
SIMVASTATIN 529 490 1 2
LEVOTHYROXINE SODIUM 475 441 2 1
WARFARIN SODIUM 444 439 3 8
FUROSEMIDE 368 340 4 6
HYDROCODONE-ACETAMINOPHEN 304 264 S3 5 7
METFORMIN HCL 301 240 6 11
LISINOPRIL 279 247 7 3
AMLODIPINE BESYLATE 278 263 8 4
METOPROLOL SUCCINATE 254 237 9 10
OMEPRAZOLE 249 227 10 5
LOSARTAN POTASSIUM 233 211 11 13
CARVEDILOL 223 190 12 25
ATORVASTATIN CALCIUM 193 182 13 15
POTASSIUM CHLORIDE 185 175 14 12
METOPROLOL TARTRATE 164 154 15 14
HYDROCHLOROTHIAZIDE 162 140 16 9
ALLOPURINOL 150 126 17 20
GABAPENTIN 147 103 18 18
CITALOPRAM HBR 138 105 19 17
NAMENDA 127 127 20 48
PRAVASTATIN SODIUM 117 86 21 23
LOVASTATIN 94 88 22 53
PAROXETINE HCL 93 90 23 45
CHLORTHALIDONE 89 78 24 78
ZOLPIDEM TARTRATE 82 45 25 19
ALENDRONATE SODIUM 79 75 26 22
ATENOLOL 79 67 26 16
SPIRONOLACTONE 78 58 28 32
SERTRALINE HCL 71 53 29 21
KLOR-CON 10 70 58 30 68
DONEPEZIL HCL 67 67 31 33
KLOR-CON M20 67 61 31 60
CLOPIDOGREL 65 62 33 56
TRIAMTERENE-HCTZ 65 65 33 26
MELOXICAM 65 53 33 44
BENAZEPRIL HCL 64 64 36 46
GEMFIBROZIL 62 50 37 61
DIGOXIN 61 61 38 27
ROPINIROLE HCL 58 58 39 67
PLAVIX 57 52 40 81
NEXIUM 57 32 40 47
SULFAMETHOXAZOLE-TRIMETHOPRIM 56 55 42 140
RAMIPRIL 52 45 43 116
ENALAPRIL MALEATE 52 48 43 50
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.